Literature DB >> 2903246

Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors.

W Kazmierski1, W S Wire, G K Lui, R J Knapp, J E Shook, T F Burks, H I Yamamura, V J Hruby.   

Abstract

A series of conformationally restricted, cyclic octapeptides containing a conformationally stable tetrapeptide sequence related to somatostatin, -Tyr-D-Trp-Lys-Thr-, as a template, were designed and synthesized with the goal of developing highly potent and selective mu opioid antagonists with minimal or no somatostatin-like activity. Three distinct structures of the peptide became targets of chemical modifications and constraints; the N- and C-terminal amino acids and the cyclic 20-membered ring moiety. Based on the conformational analysis of active and inactive analogues of the parent peptide D-Phe1-Cys2-Tyr3-D-Trp4-Lys5-Thr6-Pen7+ ++-Thr8-NH2, CTP (Kazmierski, W.; Hruby, V. J. Tetrahedron 1988, 44, 697-710), we designed analogues to include the tetrahydroisoquinolinecarboxylate (Tic) moiety as the N-terminal amino acid instead of D-Phe, since Tic can exist only as a gauche (-) or a gauche (+) conformer. In this series, the following peptides were synthesized and pharmacologically evaluated: D-Tic-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2 (TCTP), D-Tic-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (TCTOP), and D-Tic-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (TCTAP). In rat brain membrane opioid radioligand binding assays, all three peptides displayed high affinity for mu opioid receptors (IC50 = 1.2, 1.4, 1.2 nM, respectively), and exceptional mu vs delta opioid receptor selectivity: 7770, 11,396, and 1060, respectively. TCTOP and TCTAP also possess exceptional mu vs somatostatin receptor selectivity: 14,574 and 28,613, respectively. In the peripheral in vitro GPI bioassay, TCTP, TCTOP, and TCTAP were highly effective antagonists of the potent mu opioid receptor agonist PL017, with pA2 = 8.69 for TCTAP, 8.10 for TCTP, and 7.38 for TCTOP. Our results show that a 10-fold higher affinity and selectivity for mu opioid receptors (in both central and peripheral studies) over delta and somatostatin receptor was gained as a result of the D-Tic1 substitution. These three peptides, TCTP, TCTOP, and TCTAP, are the most potent and selective mu opioid antagonists known. CTP has been shown to possess prolonged biological action, much longer than that of naloxone. This renders these analogues potentially useful ligands for investigating the physiological functions of the mu opioid receptor. Analogues of TCTP in which the 20-membered disulfide ring was contracted by deletion of D-Trp4, and/or Lys5, and/or Thr6 led to compounds with greatly reduced potency at the mu opioid receptor.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2903246     DOI: 10.1021/jm00119a019

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  In vivo pharmacological resultant analysis reveals noncompetitive interactions between opioid antagonists in the rat tail-withdrawal assay.

Authors:  E A Walker
Journal:  Br J Pharmacol       Date:  2006-10-30       Impact factor: 8.739

Review 2.  Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations.

Authors:  V J Hruby; F al-Obeidi; W Kazmierski
Journal:  Biochem J       Date:  1990-06-01       Impact factor: 3.857

3.  Engineering strategy to improve peptide analogs: from structure-based computational design to tumor homing.

Authors:  David Zanuy; Francisco J Sayago; Guillem Revilla-López; Gema Ballano; Lilach Agemy; Venkata Ramana Kotamraju; Ana I Jiménez; Carlos Cativiela; Ruth Nussinov; April M Sawvel; Galen Stucky; Erkki Ruoslahti; Carlos Alemán
Journal:  J Comput Aided Mol Des       Date:  2012-12-14       Impact factor: 3.686

Review 4.  Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.

Authors:  Victor J Hruby; Minying Cai
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013       Impact factor: 13.820

Review 5.  The role of δ-opioid receptors in learning and memory underlying the development of addiction.

Authors:  Paul Klenowski; Michael Morgan; Selena E Bartlett
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

6.  Endogenous activation of mu and delta-1 opioid receptors is required for long-term potentiation induction in the lateral perforant path: dependence on GABAergic inhibition.

Authors:  C R Bramham; J M Sarvey
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

Review 7.  Organic chemistry and biology: chemical biology through the eyes of collaboration.

Authors:  Victor J Hruby
Journal:  J Org Chem       Date:  2009-12-18       Impact factor: 4.354

8.  Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors.

Authors:  Manu Jaggi; Sudhanand Prasad; Anu T Singh; R Praveen; Sarjana Dutt; Archana Mathur; Rajan Sharma; Neena Gupta; Rinku Ahuja; Rama Mukherjee; Anand C Burman
Journal:  Invest New Drugs       Date:  2008-01-24       Impact factor: 3.850

9.  Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in rats.

Authors:  Caren L Steinmiller; Alice M Young
Journal:  Psychopharmacology (Berl)       Date:  2007-09-19       Impact factor: 4.530

10.  Comparing analgesia and mu-opioid receptor internalization produced by intrathecal enkephalin: requirement for peptidase inhibition.

Authors:  Wenling Chen; Bingbing Song; Lijun Lao; Orlando A Pérez; Woojae Kim; Juan Carlos G Marvizón
Journal:  Neuropharmacology       Date:  2007-08-02       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.